Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable locally advanced esophageal...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy